Acute on Chronic Liver Failure Market to Surge as Key Companies Such as Grifols Therapeutics, Versantis AG, Promethera Biosciences, and Others are Exploring the Therapeutics Segment, Assesses DelveInsight
The report also offers current Acute on Chronic Liver Failure therapy algorithms, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Acute on Chronic Liver Failure market.
Key Takeaways from the Acute on Chronic Liver Failure Market Report
According to DelveInsight estimates, the Acute on Chronic Liver Failure market size is expected to grow significantly at a considerable CAGR by 2032.
Both hepatic (alcohol-induced liver injury) and extrahepatic (bacterial infections or gastrointestinal hemorrhage) disorders were the most common precipitating disorders for acutely decompensated cirrhosis, with or without ACLF.
Globally, key Acute on Chronic Liver Failure companies such as Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT, and others are developing novel Acute on Chronic Liver Failure drugs that can be available in the Acute on Chronic Liver Failure market in the upcoming years.
Promising Acute on Chronic Liver Failure therapies in the pipeline include Albutein (PE-A 5%), HepaStem, VS-01, and others.
In November 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients suffering from liver diseases with significant unmet medical needs, announced the highlights of its Pipeline Day events, which reviewed the Company's clinical progress and recent strategic updates.
In September 2022, In a small-time buyout, Genfit SA agreed to acquire Versantis, a Swiss startup, for CHF40 million upfront.
In June 2022, Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, announced today data demonstrating that both single and repeated intraperitoneal administrations of VS-01 reduced the concentrations of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) associated with ACLF.
Discover more about therapies set to grab major Acute on Chronic Liver Failure market share @ Acute on Chronic Liver Failure Market Report- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Overview
The term 'acute-on-chronic liver failure (ACLF)' refers to a sudden and potentially fatal worsening of clinical conditions in patients with cirrhosis or chronic liver disease. ACLF is a severe condition with a high morbidity and mortality rate. The European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium defines ACLF as the failure of one of the six major organ systems. The CLIF-C Organ Failure scale is used to assess the failure of each organ system.
According to NACSELD, the most common organ system failures were brain (36%), circulatory (16%), kidney (13%), and respiratory (9%). 3 The observed 30-day mortality rate gradually increased from 4% in patients with no OF to 27%, 49%, 64%, and 77% in patients with 1, 2, 3, or 4 OFs, respectively.
Learn more about the Acute on Chronic Liver Failure treatment guidelines @ ACLF Guidelines
Acute on Chronic Liver Failure Epidemiological Insights
According to Delveinsight, grade 1 cases accounted for the maximum number of ACLF cases.
DelveInsight's analysis shows that the cases of ACLF show an increasing trend in the forecasted period (2019-2032) in the United States.
The ACLF market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Prevalence of ACLF
Prevalent cases of ACLF by Grades
Organ failures associated with ACLF
Potential precipitating events of ACLF
Download the report to understand which factors are driving Acute on Chronic Liver Failure epidemiology trends @ Acute on Chronic Liver Failure Epidemiological Insights-https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Treatment Market
There is currently no specific treatment available for ACLF patients. ACLF management includes etiology-based treatment, controlling and treating complications, providing an artificial liver support system, and performing a liver transplant. Patients with ACLF should preferably be admitted to transplant centers. Organ functions must be closely monitored, and organ-specific treatment is required to prevent multiorgan failure.
The main principles of management in these patients are to support each failing organ and promote hepatic gland recovery. The current treatment consists of detoxification devices, antiviral therapy, and liver transplantation.
To know more about Acute on Chronic Liver Failure treatment options, visit @ ACLF Drugs- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Pipeline Therapies
Albutein (PE-A 5%)
Acute on Chronic Liver Failure Key Companies
Tianjin Weikai Bioeng., Ltd.
Steminent Biotherapeutics Inc.
Martin Pharmaceuticals, Inc.
GNI Group Ltd.
Learn more about the Acute on Chronic Liver Failure therapies in clinical trials @ New Treatment for ACLF- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Acute on Chronic Liver Failure Market Dynamics
Many medical factors influence the global acute liver failure treatment market. Drug-induced acute liver failure is one of the common factors driving the acute liver treatment market. For example, excessive acetaminophen dosage has been identified as the leading cause of acute liver failure in the United States.
As per DelveInsight analysis, Among the EU-5 countries, Germany accounts for the highest market size of the Acute-on-Chronic Liver Failure (ACLF) Market.
In the last five years, the field of ACLF has moved very quickly to meet the current unmet need. The availability of a large volume of published data from the East and West has allowed the initial definitions to be reassessed. Attempts to prevent, mitigate, or reverse the ongoing injury would allow for the restoration of hepatic synthetic functions and the reversal of liver damage. Early predictors of mortality and irreversibility of the condition would pave the way for such patients to receive priority liver transplantation.
Scope of the Acute on Chronic Liver Failure Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute on Chronic Liver Failure Companies: Promethera Biosciences, Akaza Bioscience, RHEACELL, Tianjin Weikai Bioeng., Ltd., Steminent Biotherapeutics Inc., Martin Pharmaceuticals, Inc., GNI Group Ltd., Versantis, GENFIT (EPA: GNFT), and others
Key Acute on Chronic Liver Failure Therapies: Albutein (PE-A 5%), HepaStem, VS-01, and others
Therapeutic Assessment: Acute on Chronic Liver Failure current marketed and emerging therapies
Acute on Chronic Liver Failure Market Dynamics: Acute on Chronic Liver Failure market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Acute on Chronic Liver Failure Market Access and Reimbursement
Discover more about Acute on Chronic Liver Failure drugs in development @ ACLF Clinical Trials- https://www.delveinsight.com/sample-request/acute-on-chronic-liver-failure-aclf-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Acute on Chronic Liver Failure Market Key Insights
2. Acute on Chronic Liver Failure Market Report Introduction
3. Acute on Chronic Liver Failure Market Overview at a Glance
4. Acute on Chronic Liver Failure Market Executive Summary
5. Disease Background and Overview
6. Acute on Chronic Liver Failure Treatment and Management
7. Acute on Chronic Liver Failure Epidemiology and Patient Population
8. Patient Journey
9. Acute on Chronic Liver Failure Marketed Drugs
10. Acute on Chronic Liver Failure Emerging Drugs
11. Seven Major Acute on Chronic Liver Failure Market Analysis
12. Acute on Chronic Liver Failure Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Acute on Chronic Liver Failure Market Drivers
16. Acute on Chronic Liver Failure Market Barriers
17. Unmet Needs
18. SWOT Analysis
20. DelveInsight Capabilities
22. About DelveInsight
Get in touch with our Business executive @ Healthcare Due Diligence Services- https://www.delveinsight.com/consulting?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Assistant Manager (Marketing & Branding)
Request for Sample Copy of the Report at:
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute on Chronic Liver Failure Market to Surge as Key Companies Such as Grifols Therapeutics, Versantis AG, Promethera Biosciences, and Others are Exploring the Therapeutics Segment, Assesses DelveInsight here
News-ID: 2841217 • Views: 234
More Releases from DelveInsight Business Research
Relapsed/Refractory Acute Myeloid Leukemia Pipeline Drugs and Companies Insight …
Relapsed/Refractory Acute Myeloid Leukemia pipeline constitutes 50+ key companies continuously working towards developing 50+ Relapsed/Refractory Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Relapsed/Refractory Acute Myeloid Leukemia Overview Relapsed/Refractory Acute Myeloid Leukemia Myeloid Leukemia which means the leukemia has come back after treatment and remission. Refractory AML means the leukemia did not respond to treatment. AML relapse affects
Ankylosing Spondylitis Pipeline Drugs and Companies Insight Report (2023): Analy …
Ankylosing Spondylitis pipeline constitutes 40+ key companies continuously working towards developing 40+ Ankylosing Spondylitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Ankylosing Spondylitis Overview Ankylosing Spondylitis, is a form of arthritis that primarily affects the spine. It causes severe inflammation of the spinal joints (Vertebrae) that can lead to chronic pain and discomfort. The hallmark feature of Ankylosing spondylitis is
Amyloid light-chain amyloidosis Pipeline Drugs and Companies Insight Report (202 …
Amyloid light-chain amyloidosis pipeline constitutes 10+ key companies continuously working towards developing 10+ Amyloid light-chain amyloidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Amyloid light-chain amyloidosis Overview "Amyloid light-chain amyloidosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyloid light-chain amyloidosis Market. The Amyloid light-chain amyloidosis Pipeline report
Small Fiber Neuropathy Pipeline Appears Robust With 3+ Key Pharma Companies Acti …
DelveInsight's, "Small Fiber Neuropathy Pipeline Insight, 2023," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Small Fiber Neuropathy pipeline landscape. It covers the Small Fiber Neuropathy pipeline drug profiles, including Small Fiber Neuropathy clinical trials and nonclinical stage products. It also covers the Small Fiber Neuropathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products
More Releases for Liver
Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Im …
Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Main Benefits - Helps Protect The Liver From Harmful Toxins Side Effects - No Major Side Effects Reported Price - $39.97/bottle Availability - Only Official website ▻Official Website - https://bit.ly/3uB8LFO Bridport Health Reviews - Is it a 100% natural liver cleansing formula? Are the 's ingredients 100% natural & safe? Clinically proven? Read the ingredients & benefits before buying. Price
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver
Global Fatty Liver Disease Drugs Market : Global Fatty Liver Disease Drugs Marke …
Research By Markets adds "Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Countryc - By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)" to its online repository. More information: https://www.researchbymarkets.com/report/global-fatty-liver-disease-drugs-market-by-type-ald-nafld-by-stages-of-ald-and-nafld-by-region-by-country-opportunities-and-forecast-2017-2022-by-ald-stages-alcoholic-steatosis-alcoholic-steatohepatitis-ash-5300.html Executive Summary A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global
Global Liver Function Tests Market: Rising Cases of Liver Diseases to be Biggest …
Liver function tests (LFT) are blood tests that are used to assess the state of liver and biliary system. The liver processes and filters the blood as it circulates through the body. It performs many vital functions that include preparing blood clotting proteins, metabolization of nutrients, and detoxification of harmful substances. The cells in the liver contain enzymes that are responsible for carrying out the chemical reactions. When liver cells
Widespread Prevalence of Chronic Liver Ailments Fuels Global Liver Diseases Ther …
Widespread prevalence of liver diseases and disorders, increasing geriatric population, and prevalence of unmet medical needs in the case of liver cancer are the primary factors augmenting the demand for effective liver disease therapeutics. Additionally, emerging economies are focusing on fuel vaccination drives to eradicate chronic ailments, which will also give a boost to the global market for liver disease therapeutics. Compiled with the intent of providing a comprehensive snapshot
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production